

Request for Prior Authorization Select Topical Agents

FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name		DOB	
Patient address			I	
Provider NPI	Prescriber name		Phone	
Prescriber address			Fax	
Pharmacy name	Address		Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax	NDC		
Prior authorization (PA) is required for select topical agents. Payment for a non-preferred agent will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following criteria are met: 1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations (note, only FDA-approved indications for each drug and specific dosage form will be considered); and 2. Patient has a diagnosis of plaque psoriasis with total overall involvement on scalp and non-scalp areas ≤ 25% of the body surface area (BSA) at baseline. Total non-scalp BSA should not exceed 20%; and a. Patient has documentation of an adequate trial and therapy failure of combination therapy with a preferred medium to high potency topical corticosteroid and a preferred topical vitamin D analog for a minimum of 4 consecutive weeks; or 3. Patient has a diagnosis of seborrheic dermatitis; and a. Patient has documentation of an adequate trial and therapy failure of combination therapy with a preferred topical antifungal for a minimum of 4 consecutive weeks; or 4. Patient has a diagnosis of mild to moderate atopic dermatitis; and a. Patient has failed to respond to good skin care and regular use of emollients; and b. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; or c. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; or c. Patient has documentation of an adequate trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.				
Preferred Non-Preferred ☐ Vtama ☐ Zoryve				
Strength	Usage Instructions	Quantity	Day's Supply	
Diagnosis:				
□ Plaque Psoriasis				
Preferred Medium to High Potency Topical Corticosteroid Trial: Drug name & dose:Trial dates: Failure reason:				

Request for Prior Authorization Select Topical Agents

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Preferred Topical Vitamin D Analog Trial:	
Drug name & dose:	
Failure reason:	
Is total overall BSA ≤ 25%? ☐ Yes	□ No
Is total non-scalp BSA ≤ 20%? ☐ Yes ☐ No	
□ Seborrheic Dermatitis	
Preferred Topical Corticosteroid Trial: Scalp Nonscalp Drug name & dose: Failure reason:	Trial dates:
Preferred Topical Antifungal Trial: Drug name & dose: Failure reason:	
☐ Mild to moderate atopic dermatitis	
Preferred Medium to High Potency Topical Corticosteroid Tria Drug name & dose: Failure reason:	Trial dates:
Preferred Topical Immunomodulator Trial: Drug name & dose: Failure reason:	
Has patient failed to respond to good skin care and regular use of	emollients? □ Yes □ No
Medical or contraindication reason to override trial requirements:	
ttach lab results and other documentation as necessary.	
	e of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary, by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.